NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 124 filers reported holding NGM BIOPHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4 | -63.6% | 4,114 | 0.0% | 0.00% | – |
| Q2 2023 | $11 | -45.0% | 4,114 | -18.1% | 0.00% | – |
| Q1 2023 | $20 | -31.0% | 5,022 | -13.7% | 0.00% | – |
| Q4 2022 | $29 | -100.0% | 5,817 | 0.0% | 0.00% | -100.0% |
| Q3 2022 | $76,000 | +4.1% | 5,817 | +1.7% | 0.00% | 0.0% |
| Q2 2022 | $73,000 | +21.7% | 5,721 | +45.5% | 0.00% | – |
| Q1 2022 | $60,000 | – | 3,933 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $79,175,000 | 44.14% |
| Ponoi II Management, LLC | 1,298,908 | $27,303,000 | 40.46% |
| Column Group LLC | 15,396,116 | $323,626,000 | 36.81% |
| Ponoi Management, LLC | 1,298,908 | $27,303,000 | 24.24% |
| Euclidean Capital LLC | 832,274 | $17,494,000 | 8.50% |
| StepStone Group LP | 1,573,357 | $33,072,000 | 2.14% |
| Octagon Capital Advisors LP | 200,000 | $4,204,000 | 1.04% |
| Redmile Group, LLC | 2,505,118 | $52,658,000 | 0.92% |
| BVF INC/IL | 955,000 | $20,074,000 | 0.78% |
| Boxer Capital, LLC | 500,000 | $10,510,000 | 0.37% |